Fate Therapeutics Stock Discussion

$Fate Therapeutics(FATE.US)$
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...

$Fate Therapeutics(FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy

$Fate Therapeutics(FATE.US)$
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

$Fate Therapeutics(FATE.US)$ Press Release: Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Dow Jones· 1 min ago

$Fate Therapeutics(FATE.US)$ GAAP EPS of -$0.46 beats by $0.12, revenue of $1.94M beats by $1.04M